Nanoparticles Could Improve Cancer Vaccines
the Cancer Therapy Advisor take:
According to new findings published in the journal ACS Nano, researchers have developed a novel approach to deliver cancer vaccines via stealthy nanoparticles.
The researchers found that this method successfully halted tumor growth when tested in mice. For the study, the researchers injected the nanoparticles into mice, and found that the particles entered the mice's lymph nodes while having no way of attracting the attention of circulating immune cells. Once inside the lymph nodes, a subset of macrophages engulfed the nanoparticles.
When the researchers inserted molecules that signal killer T cells into the nanoparticles, they found that tumor growth was inhibited much more compared with existing vaccines. The researchers say that most cancer vaccines in development are designed to attract macrophages and dendritic cells, which in turn signal killer T cells to attack cancer cells; however, this approach has not been greatly successful.
The team of researchers wanted to determine whether a subset of macrophages inside the lymph nodes could be activated by a cancer vaccine without attracting the attention of macrophages and dendritic cells that would use up the antibodies in the cancer vaccine. To do so, they hid them in stealthy nanoparticles.
Researchers developed a novel approach to deliver cancer vaccines via stealthy nanoparticles.
Cancer vaccines have recently emerged as a promising approach for killing tumor cells before they spread. But so far, most clinical candidates haven't worked that well. Now, scientists have developed a new way to deliver vaccines that successfully stifled tumor growth when tested in laboratory mice. And the key, they report in the journal ACS Nano, is in the vaccine's unique stealthy nanoparticles.
Hiroshi Shiku, Naozumi Harada and colleagues explain that most cancer vaccine candidates are designed to flag down immune cells, called macrophages and dendritic cells, that signal "killer" T cells to attack tumors. The problem is that approaches based on targeting these generally circulating immune cells have not been very successful.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Plastics and Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer